← Back to Home

New oral drug for refractory herpes: FDA approves pritelivir for immunocompromised adults

When commonly used antiviral drugs fail to heal herpes lesions, immunocompromised patients often face prolonged treatment. The newly approved Hovilpri blocks viral replication through a different mechanism, and a randomized trial showed that it can increase the rate of complete lesion healing within 28 days. However, its approved scope of use and long-term benefits must still be clearly distinguished.

By SURL BioNews

For immunocompromised people, skin and mucosal lesions caused by herpes simplex virus (HSV) can be recurrently painful wounds that are slow to heal. When commonly used antiviral drugs fail, treatment options narrow. The U.S. Food and Drug Administration (FDA) has approved the oral drug Hovilpri (generic name: pritelivir), giving these patients an additional option with a different mechanism of action.

Asahi Kasei Therapeutics, Asahi Kasei’s pharmaceutical business, announced the approval on October 9, and Asahi Kasei issued a related announcement on October 13. The FDA confirmed that the indication is limited to immunocompromised adults whose HSV skin and mucosal lesions have not responded to treatment with acyclovir, valacyclovir, or famciclovir. The company further explained that patients do not need prior laboratory evidence of viral drug resistance; failure to respond to treatment and confirmed drug resistance are two concepts that need to be distinguished.

Pritelivir was developed by AiCuris, which is now part of Asahi Kasei Therapeutics. It is an oral helicase–primase inhibitor that acts on the enzymatic machinery required for viral replication. The company noted that nucleoside analogues such as acyclovir require activation by viral thymidine kinase, and mutations affecting this enzyme may reduce drug susceptibility. Pritelivir offers another point of intervention and adds an oral treatment option for eligible patients.

The key evidence supporting approval came from Part C of the Phase 3 PRIOH-1 trial, in which 101 immunocompromised adults were randomized and treated, comparing pritelivir with existing therapies selected by the study physicians. Participants included patients with hematologic diseases, transplants, HIV infection, and other clinical circumstances involving immunosuppression. By day 28, 63% of patients in the pritelivir group had complete healing of all lesions, compared with 34% in the control group.

The company reported an adjusted treatment difference of 28.4 percentage points, with a 95% confidence interval of 9.6 to 47.3 percentage points and a p-value of 0.0047, supporting a statistically significant difference between the groups on the primary endpoint. If lesions had improved but had not completely healed, the trial allowed treatment to be extended to 42 days. However, this was an open-label study, and the control treatments were selected by physicians. The results show the overall benefit compared with this set of existing therapies and cannot be directly interpreted as showing the same advantage over each individual drug.

Regarding safety, the FDA listed headache as the most common adverse reaction and cautioned that drug interactions require attention. The prescribing information released by the company also noted that certain acid-suppressing drugs may reduce pritelivir exposure and affect treatment efficacy. Thus, although the oral formulation makes treatment more convenient, patients’ existing medications still need to be included in the assessment.

The clinical significance of this approval lies in helping refractory lesions heal in specific patients. HSV may still remain latent and reactivate, and wound healing within 28 days does not mean that the infection has been eliminated or that long-term prevention of recurrence has been demonstrated. This approval does not extend to common herpes episodes in people with normal immune function. The new drug’s value lies first with adult patients for whom existing treatments have been ineffective.

References

  1. Asahi Kasei
  2. U.S. Food and Drug Administration
  3. Asahi Kasei Therapeutics